Applied DNA Sciences (APDN) 10-Q 12 May 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Mar. 31, 2014	5-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'APPLIED DNA SCIENCES INC	'
Entity Central Index Key	'0000744452	'
Trading Symbol	'apdn	'
Current Fiscal Year End Date	'--09-30	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	808,596,863
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Sep. 30, 2013
Current assets:	'	'
Cash and cash equivalents	$1,988,184	$6,360,301
Accounts receivable, net of allowance of $36,757 and $62,415 at March 31, 2014 and September 30, 2013, respectively	605,995	672,638
Prepaid expenses	108,234	174,096
Total current assets	2,702,413	7,207,035
Property, plant and equipment, net of accumulated depreciation of $575,507 and $409,629 at March 31, 2014 and September 30, 2013, respectively	647,492	695,995
Other assets:	'	'
Deposits	57,988	51,260
Intangible assets:	'	'
Intellectual property, net of accumulated amortization and impairment of $209,550 and $163,403 at March 31, 2014 and September 30, 2013, respectively	374,529	420,676
Total Assets	3,782,422	8,374,966
Current liabilities:	'	'
Accounts payable and accrued liabilities	1,319,343	966,977
Deferred revenue	415,989	148,503
Total current liabilities	1,735,332	1,115,480
Warrant liability	2,367,266	2,643,449
Total liabilities	4,102,598	3,758,929
Commitments and contingencies	'	'
Stockholders' (Deficit) Equity	'	'
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2014 and September 30, 2013	'	'
Common stock, par value $0.001 per share; 1,350,000,000 shares authorized; 808,596,863 and 786,526,955 shares issued and outstanding as of March 31, 2014 and September 30, 2013, respectively	808,597	786,527
Additional paid in capital	194,606,924	190,523,121
Accumulated deficit	-195,735,697	-186,693,611
Total stockholders' (deficit) equity	-320,176	4,616,037
Total Liabilities and Stockholders' (Deficit) Equity	3,782,422	8,374,966
Series A Preferred stock	'	'
Stockholders' (Deficit) Equity	'	'
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2014 and September 30, 2013	'	'
Series B Preferred stock	'	'
Stockholders' (Deficit) Equity	'	'
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2014 and September 30, 2013	'	'

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Mar. 31, 2014	Sep. 30, 2013
Allowance on accounts receivable (in dollars)	$36,757	$62,415
Accumulated depreciation on property, plant and equipment (in dollars)	575,507	409,629
Accumulated amortization and impairment on intellectual property (in dollars)	$209,550	$163,403
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	1,350,000,000	1,350,000,000
Common stock, shares issued	808,596,863	786,526,955
Common stock, shares outstanding	808,596,863	786,526,955
Series A Preferred stock	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred stock	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'	'	'
Revenues	$637,146	$344,605	$1,234,500	$662,275
Operating expenses:	'	'	'	'
Selling, general and administrative	3,297,739	2,754,407	7,143,317	5,275,574
Research and development	359,782	176,485	819,086	324,151
Depreciation and amortization	106,810	21,830	212,025	42,825
Total operating expenses	3,764,331	2,952,722	8,174,428	5,642,550
LOSS FROM OPERATIONS	-3,127,185	-2,608,117	-6,939,928	-4,980,275
Other income (expense):	'	'	'	'
Interest income (expense), net	239	405	673	405
Other income (expense), net	-79,389	'	76,028	'
Gain (loss) on change in fair value of warrant liability	455,899	-519,919	-2,178,859	-6,852,518
Net loss before provision for income taxes	-2,750,436	-3,127,631	-9,042,086	-11,832,388
Income taxes (benefit)	'	'	'	'
NET LOSS	($2,750,436)	($3,127,631)	($9,042,086)	($11,832,388)
Net loss per share-basic and diluted (in dollars per share)	$0	$0	($0.01)	($0.02)
Weighted average shares outstanding-	'	'	'	'
Basic and diluted (in shares)	808,248,340	680,399,988	798,970,750	664,993,844

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net loss	($9,042,086)	($11,832,388)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	212,025	42,825
Fair value of vested options issued to officers, directors and employees	1,313,331	873,023
Change in fair value of warrant liability	2,178,859	6,852,518
Equity based compensation	'	13,238
Common stock issued for consulting services	337,500	'
Bad debt expense	16,144	'
Change in operating assets and liabilities:	'	'
Accounts receivable	50,499	-110,803
Prepaid expenses and deposits	59,134	54,762
Accounts payable and accrued liabilities	344,572	217,714
Deferred revenue	267,486	'
Net cash used in operating activities	-4,262,536	-3,889,111
Cash flows from investing activities:	'	'
Purchase of property and equipment	-109,581	-30,061
Net cash used in investing activities	-109,581	-30,061
Cash flows from financing activities:	'	'
Net proceeds from sale of common stock	'	2,000,000
Proceeds from sale of Series A preferred stock	'	5,500,000
Proceeds from exercise of warrants	'	150,000
Purchase and cancellation of previously issued warrants	'	-50,000
Net cash provided by financing activities	'	7,600,000
Net (decrease) increase in cash and cash equivalents	-4,372,117	3,680,828
Cash and cash equivalents at beginning of period	6,360,301	724,782
Cash and cash equivalents at end of period	1,988,184	4,405,610
Supplemental Disclosures of Cash Flow Information:	'	'
Cash paid during period for interest	'	'
Cash paid during period for taxes	'	'
Non-cash investing and financing activities:	'	'
Common stock issued in exchange for previously incurred debt	'	'
Common stock issued for cashless exercise of options and warrants	19,570	'
Property, plant and equipment acquired, and included in accounts payable	$7,794	'

SUMMARY_OF_ACCOUNTING_POLICIES

SUMMARY OF ACCOUNTING POLICIES	6 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
SUMMARY OF ACCOUNTING POLICIES	'
	NOTE A — SUMMARY OF ACCOUNTING POLICIES
	General
	The accompanying condensed consolidated financial statements as of March 31, 2014 and for the three and six months ended March 31, 2014 and 2013 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements.
	In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended March 31, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2014. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated  financial statements as of and for the year ended September 30, 2013 and footnotes thereto included in the Company’s Annual Report on Form 10-K and Form 10-K/A filed with the SEC.
	The condensed consolidated balance sheet as of September 30, 2013 contained herein has been derived from the audited consolidated financial statements as of September 30, 2013, but do not include all disclosures required by GAAP.
	Business and Basis of Presentation
	On September 16, 2002, Applied DNA Sciences, Inc. (the “Company”) was incorporated under the laws of the State of Nevada. Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware.  The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe.  To date, the Company has had a limited operating history, and as a result, its operations have produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses.  Consequently, its operations are subject to all the risks inherent in the establishment of a biotechnology company. For the period from inception through March 31, 2014, the Company has accumulated losses of $195,735,697.
	The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Applied DNA Operations Management, Inc., APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations.
	Use of Estimates
	The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures.  Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  The most complex and subjective estimates include; recoverability of long-lived assets, including the value assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies and allowance for doubtful accounts.  Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the condensed consolidated interim financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates.
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”).  ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured.  Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts.  Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded.  The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required.  At March 31, 2014 and September 30, 2013, the Company recorded deferred revenue of $415,989 and $148,503, respectively.
	Revenue Recognition, continued
	Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer.  Consideration received is allocated among the separate units of accounting based on their respective selling prices.  The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available.  The applicable revenue recognition criteria are then applied to each of the units.
	Revenue for a government contract award, which supports our development efforts on specific projects, is recognized as milestones are achieved as per the contract.  The Company recognized revenue of approximately $25,000 and $50,000 from this contract award during the three and six month periods ended March 31, 2014, respectively.
	Cash Equivalents
	For the purpose of the accompanying unaudited condensed consolidated financial statements, all highly liquid investments with a maturity of three months or less are considered to be cash equivalents.
	Accounts Receivable
	The Company provides an allowance for doubtful accounts equal to the estimated uncollectible amounts.  The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable.  It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change.  At March 31, 2014 and September 30, 2013, the Company has an allowance for doubtful accounts of $36,757 and $62,415, respectively.  The Company writes off receivables that are deemed uncollectible.  The Company wrote-off $16,801 and $41,801, respectively, of accounts receivable that was previously reserved for during the three and six month periods ended March 31, 2014.
	Income Taxes
	The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns.  Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes include, but not limited to, accounting for intangibles, warrants, equity based compensation and depreciation and amortization.
	The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all of the deferred tax asset will not be realized.  During the year ended September 30, 2013 and the three and six months ended March 31, 2014, the Company incurred losses from operations. Based upon these results and the trends in the Company’s performance projected for the remainder of fiscal year 2014, it is more likely than not that the Company will not realize any benefit from the deferred tax assets recorded by the Company in previous periods.  Management makes judgments as to the interpretation of tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability.  In management’s opinion, adequate provisions for income taxes have been made for all years.  If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.  The Company has identified its federal tax return and its state tax return in New York as “major” tax jurisdictions.  Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company condensed consolidated financial statements.
	The Company’s evaluation was performed for tax years 2009 through 2012.  The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position.  It is the Company’s policy to accrue interest and penalties on unrecognized tax benefits as components of income tax provision.  The Company did not have any accrued interest or penalties as of March 31, 2014 and September 30, 2013.
	Property Plant and Equipment
	Property plant and equipment are stated at cost and depreciated using the straight line method over their estimated useful lives.  The estimated useful lives for computer equipment, lab equipment and furniture is 3 to 5 years and leasehold improvements are amortized over the shorter of their useful life or the lease term. Property plant and equipment consist of:
		March 31,		September 30,
		2014		2013
		(unaudited)
	Computer equipment	$	69,182	$	43,555
	Lab equipment		739,889		657,735
	Furniture		164,997		164,997
	Leasehold improvements		248,931		239,337
	Total		1,222,999		1,105,624
	Accumulated depreciation		575,507		409,629
	Property and equipment, net	$	647,492	$	695,995
	Depreciation expense for the three and six month periods ended March 31, 2014 was $83,864 and $165,878, respectively.  Depreciation expense for the three and six month periods ended March 31, 2013 was $21,830 and $42,825, respectively.
	Impairment of Long-Lived Assets
	The Company accounts for its long-lived assets in accordance with ASC 360, Property, Plant and Equipment (“ASC 360”).  ASC 360 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The Company evaluates its long lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period.  The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows.  Should impairment in value be indicated, the carrying value of long-lived assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset.  ASC 360 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.
	Segment Information
	The Company follows the provisions of ASC 280, Segment Reporting (“ASC 280”).  ASC 280 establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders.  ASC 280 also establishes standards for related disclosures about products and services and geographic areas.  Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance.  The information disclosed herein, materially represents all of the financial information related to the Company’s single principal operating segment.
	Net Loss Per Share
	The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share.  Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period.  Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.
	For the three and six months ended March 31, 2014 and 2013, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.
	Fully diluted shares outstanding were 951,183,299 and 939,779,709 for the three and six month periods ended March 31, 2014, respectively.
	Fully diluted shares outstanding were 813,157,960 and 797,751,816 for the three and six month periods ended March 31, 2013, respectively.
	Stock Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation (“ASC 718”).  ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values.  Under the provisions of ASC 718, stock-based compensation costs is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant).  The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions:  expected volatility, dividend rate, risk free interest rate and the expected life.  The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.  Stock-based compensation expense recognized under ASC 718 for the three and six month periods ended March 31, 2014 were $547,784 and $1,313,331, respectively, and for the three and six month periods ended March 31, 2013 were $455,157 and $873,023, respectively.
	As of March 31, 2014, 192,484,972 employee stock options were outstanding with options to purchase 131,107,972 shares vested and exercisable.
	Concentrations
	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables.  The Company places its cash and temporary cash investments with high credit quality institutions.  At times, such investments may be in excess of the FDIC insurance limit.
	The Company’s revenues earned from sale of products and services for the three month period ended March 31, 2014 included an aggregate of 16% from one customer of the Company’s total revenues. During the six month period ended March 31, 2014 no customers represented 10% or greater of the Company’s total revenues.
	The Company’s revenues earned from the sale of products and services for the three and six month periods ended March 31, 2013 included an aggregate of 66% and 59% from one and four customers of the Company’s total revenues, respectively.
	Three customers accounted for 61% and 43% of the Company’s total accounts receivable at March 31, 2014 and September 30, 2013, respectively.
	Research and Development
	The Company accounts for research and development costs in accordance with the ASC 730, Research and Development (“ASC 730”).  Under ASC 730, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.  The Company incurred research and development expenses of $359,782 and $176,485 for the three month periods ended March 31, 2014 and 2013, respectively, and $819,086 and $324,151 for the six month periods ended March 31, 2014 and 2013, respectively.
	Advertising
	The Company follows the policy of charging the costs of advertising to expense as incurred.  The Company charged to operations $22,477 and $99,352 as advertising costs for the three month periods ended March 31, 2014 and 2013, respectively, and $74,918 and $136,811 for the six month periods ended March 31, 2014 and 2013, respectively.
	Intangible Assets
	The Company amortizes its intangible assets using the straight-line method over their estimated period of benefit.  The estimated useful life for patents is five years while other intellectual property uses a seven year useful life. The Company periodically evaluates the recoverability of intangible assets and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists.  All of the Company’s intangible assets are subject to amortization.
	Fair Value of Financial Instruments
	The Company’s financial instruments are primarily composed of cash, accounts receivable, accounts payable and accrued liabilities, and warrants. The fair value of cash, accounts receivable, accounts payable and accrued liabilities, as reflected in the condensed consolidated balance sheet, approximate its fair value due to the short-term maturity of these instruments.
	The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.
The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.
For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.
As of March 31, 2014, there were no transfers in or out of Level 3 from other levels.
The fair value of each warrant is estimated using the Binomial Lattice option pricing model. Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility, in isolation, can significantly increase or decrease the fair value of the warrant. See Note H.
Recent Accounting Pronouncements
There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.
Subsequent Events
The Company has evaluated events that occurred subsequent to the balance sheet date and through the date the financial statements were available to be issued. Management concluded that no subsequent events required disclosure in the condensed consolidated financial statements.

LIQUIDITY_AND_MANAGEMENTS_PLAN

LIQUIDITY AND MANAGEMENT'S PLAN	6 Months Ended
	Mar. 31, 2014
Liquidity And Management Plan [Abstract]	'
LIQUIDITY AND MANAGEMENT'S PLAN	'
	NOTE B – LIQUIDITY AND MANAGEMENT’S PLAN
	The Company has recurring net losses, which have resulted in an accumulated deficit of $195,735,697 as of March 31, 2014.  The Company incurred a net loss of $9,042,086 and generated negative operating cash flow of $4,262,536 for the six month period ended March 31, 2014.  However, the Company has attained positive working capital of $967,081 as of March 31, 2014.  At March 31, 2014, the Company had cash and cash equivalents of $1,988,184.  The Company’s current capital resources include cash and cash equivalents and other working capital resources, and cash generated through operations.  Historically, the Company has financed its operations principally from the sale of equity securities.
	Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and ultimately, upon the Company attaining profitable operations.  The Company will require additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover the Company’s operating expenses.  If the Company is unsuccessful in obtaining the necessary additional financing, it will most likely be forced to reduce operations.
	Management believes that it will be able to raise additional funds and the Company is currently in discussions with investment bankers and potential investors regarding possible financing.  However, the Company has no formal commitments for any future funding, and may not be able to obtain additional financing on terms acceptable to it, if at all, in the future.
	The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs.  The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

ACCOUNTS_PAYABLE_AND_ACCRUED_L

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	6 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	'
	NOTE C – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
	Accounts payable and accrued liabilities at March 31, 2014 and September 30, 2013 are as follows:
		March 31,
		2014		September 30,
		(unaudited)		2013
	Accounts payable	$	986,281	$	641,302
	Accrued consulting fees		102,500		102,500
	Accrued salaries payable		152,413		220,175
	Other accrued expenses		78,149		3,000
	Total	$	1,319,343	$	966,977

WARRANT_LIABILITY

WARRANT LIABILITY	6 Months Ended
	Mar. 31, 2014
Warrant Liability [Abstract]	'
WARRANT LIABILITY	'
	NOTE D – WARRANT LIABILITY
	On December 16, 2013, Crede CG III, Ltd (“Crede”) effected the cashless exercise of 10,695,187 Series A Warrants and 7,000,000 Series B Warrants.  At December 16, 2013 (date of exercise), the Company determined the fair value of the Warrants to be $2,455,042 using the Binomial Lattice model with the following assumptions: fair value of the Company’s Common Stock $0.18 per share; dividend yield 0%; expected term: 4.55 years; risk free interest rate: 1.55%; expected volatility of: 118.89%; and an exercise price of $0.2431. The change in fair value of the warrant liability on the day of exercise amounted to a loss of $1,288,752 and was included in the results of operations.  Upon exercise, the fair value of the Series A and 7,000,000 of the Series B Warrants were reclassified to equity.
	As of March 31, 2014 the fair value of the remaining 22,411,764 Series B Warrants was $2,367,266. The fair value was determined using the Binomial Lattice model with the following assumptions: fair value of the Company’s Common Stock $0.13 per share; dividend yield 0%; expected terms 4.30 years; risk free interest rate: 1.32%; expected volatility of: 138.87%; and the expected price at which holders are likely to exercise their Warrants of $0.2431 per share.

CAPITAL_STOCK

CAPITAL STOCK	6 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
CAPITAL STOCK	'
	NOTE E - CAPITAL STOCK
	The Company is authorized to issue 1,350,000,000 shares of Common Stock as the result of a vote of stockholders conducted on January 27, 2012 which effected an increase in the authorized shares of Common Stock from 800,000,000 shares to 1,350,000,000 shares.  In addition, the Company is authorized to issue 10,000,000 shares of preferred stock with a $0.001 par value per share. As of March 31, 2014 and September 30, 2013, there were 808,596,863 and 786,526,955 shares of Common Stock issued and outstanding, respectively, and no shares of preferred stock outstanding.
	Common Stock Transactions during the six month period ended March 31, 2014:
	On December 16, 2013, Crede effected the cashless exercise of 10,695,187 Series A Warrants and 7,000,000 Series B Warrants, and the Company thereupon issued to Crede an aggregate of 18,823,073 shares of its Common Stock.
	On December 20, 2013, 2,500,000 shares of the Company’s Common Stock were issued in connection with a settlement resulting from the termination of a consulting agreement.  The fair value of the Common Stock was determined using the Company’s stock price on December 20, 2013.  The total fair value of $337,500 was charged to operations.
	On February 11, 2014, 746,835 shares of the Company’s Common Stock were issued in connection with the cashless exercise of 1,000,000 warrants to acquire the Company’s Common Stock.

STOCK_OPTIONS_AND_WARRANTS

STOCK OPTIONS AND WARRANTS	6 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
STOCK OPTIONS AND WARRANTS	'
	NOTE F - STOCK OPTIONS AND WARRANTS
	Warrants
	The following table summarizes the changes in warrants outstanding and the related prices for the shares of Common Stock issued to non-employees of the Company.  These warrants were granted in lieu of cash compensation for services performed or financing expenses in connection with the sale of Common Stock.
							Warrants
							Outstanding			Weighted				Exercisable
							Remaining			Average		Weighted		Weighted
		Exercise		Number			Contractual			Exercise		Average		Average
		Prices		Outstanding			Life (Years)			Price		Exercisable		Exercise Price
	$	0.04			2,000,000			1. 42		$	0.04		2,000,000	$	0.04
	$	0.0441			510,784			3.29		$	0.0441		510,784	$	0.0441
	$	0.0475			3,789,489			4.29		$	0.0475		3,789,489	$	0.0475
	$	0.0553			226,081			3.78		$	0.0553		226,081	$	0.0553
	$	0.071			1,000,000			0.82		$	0.071		1,000,000	$	0.071
	$	0.09			6,900,000			2.42		$	0.09		6,900,000	$	0.09
	$	0.179			100,000			1.6		$	0.179		100,000	$	0.179
	$	0.214			100,000			2.1		$	0.214		100,000	$	0.214
	$	0.2431			22,411,764			4.3		$	0.2431		22,411,764	$	0.2431
					37,038,118			3.67		$	0.1748		37,038,118	$	0.1748
	Transactions involving warrants are summarized as follows:
			Number of			Weighted Average
			Shares			Price Per Share
	Balance at October 1, 2013			59,033,305		$	0.0196
	Granted			—			—
	Exercised			(18,695,187	)		(0.2320	)
	Cancelled or expired			(3,300,000	)		(0.2330	)
	Balance,  March 31, 2014			37,038,118		$	0.1748
	Warrants , continued
	Transactions involving warrants are summarized as follows:
	On December 16, 2013, Crede effected the cashless exercise of 10,695,187 Series A Warrants and 7,000,000 Series B Warrants, and the Company thereupon issued to Crede an aggregate of 18,823,073 shares of its Common Stock.
	On February 11, 2014, 746,835 shares of the Company’s Common Stock were issued in connection with the cashless exercise of 1,000,000 warrants to acquire the Company’s common stock.
	Employee Stock Options
	In 2005, the Board of Directors and holders of a majority of the outstanding shares of Common Stock approved the 2005 Incentive Stock Plan,  In 2007, 2008 and 2012, the Board of Directors and holders of a majority of the outstanding shares of Common Stock approved various increases in the number of shares of Common Stock that can be issued as stock awards and stock options thereunder to an aggregate of 350,000,000 shares and the number of shares of Common Stock that can be covered by awards made to any participant in any calendar year to 50,000,000 shares.
	The 2005 Incentive Stock Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to the Company’s success with an award of options to purchase shares of Common Stock.  As of March 31, 2014, a total of 12,675,000 shares have been issued and options to purchase 198,488,972 shares have been granted under the 2005 Incentive Stock Plan.
	The following table summarizes the changes in options outstanding and the related prices for the shares of Common Stock issued to employees of the Company under the 2005 Incentive Stock Plan:
		Options Outstanding								Options Exercisable
		Exercise		Number			Weighted Average			Weighted Average		Number		Weighted
		Prices		Outstanding			Remaining			Exercise Price		Exercisable		Average
							Contractual							Exercise Price
							Life (Years)
	$	0.05			24,000,000			1.1		$	0.05		24,000,000	$	0.05
	$	0.0585			50,000,000			4.29		$	0.0585		50,000,000	$	0.0585
	$	0.06			30,000,000			1.26		$	0.06		30,000,000	$	0.06
	$	0.065			634,825			2.68		$	0.065		634,825	$	0.065
	$	0.068			4,770,000			2.67		$	0.068		4,770,000	$	0.068
	$	0.07			2,850,000			1.17		$	0.07		2,300,000	$	0.07
	$	0.0866			7,377,000			4.71		$	0.0866		2,000,000	$	0.0866
	$	0.09			1,500,000			1.42		$	0.09		1,500,000	$	0.09
	$	0.097			56,777,780			4.71		$	0.097		3,777,780	$	0.097
	$	0.11			5,400,000			4.21		$	0.11		5,400,000	$	0.11
	$	0.116			250,000			4.73		$	0.116		—	$	—
	$	0.117			2,000,000			4.73		$	0.117		—	$	—
	$	0.136			2,126,000			4.74		$	0.136		2,126,000	$	0.136
	$	0.16			2,500,000			4.83		$	0.16		2,500,000	$	0.16
	$	0.1799			2,099,367			3.67		$	0.1799		2,099,367	$	0.1799
	$	0.193			100,000			4.25		$	0.193		—	$	—
	$	0.2			100,000			4.13		$	0.2		—	$	—
					192,484,972			3. 45		$	0.0765		131,107,972	$	0.067
	Employee Stock Options , continued
	Transactions involving stock options issued to employees are summarized as follows:
			Number of			Weighted Average			Aggregate
			Shares			Exercise			Intrinsic
						Price Per			Value
						Share
Outstanding at October 1, 2013			121,454,192		$	0.063
Granted			71,030,780			0.0999
Exercised			—			—
Expired			—			—
Outstanding at March 31, 2014			192,484,972		$	0.0765
Vested at March 31, 2014			131,107,972					$	0.067
Non-vested at March 31, 2014			61,377,000					$	0.036
Transactions involving stock options issued to employees are summarized as follows:
On October 14, 2013, the Company granted an aggregate of 7,377,000 options to purchase the Company’s Common Stock at an exercise price of $0.0886 per share for five years to employees. 5,377,000 of these options vest at 25% each anniversary for the next four years and 2,000,000 of these options vest immediately.
On October 17, 2013, the Company granted Dr. James A. Hayward, Chairman, CEO and President and Dr. Ming-Hwa Liang, Chief Technology Officer and Secretary of the Company options to purchase 50,000,000 and 3,000,000 shares of the Company’s Common Stock, respectively, at an exercise price of $0.0970 per share for five years with vesting at 25% each anniversary for the next four years.  Also on October 17, 2013, the Company granted an aggregate of 3,777,780 options to non-employee board of director members at an exercise price of $0.0970 per share for five years with immediate vesting.
On November 28, 2013, the Company granted 250,000 options to purchase the Company’s Common Stock at an exercise price of $0.1160 per share for five years to an employee with vesting at 25% each anniversary for the next four years.
On December 2, 2013, the Company granted 2,000,000 options to purchase the Company’s Common Stock at an exercise price of $0.1170 per share for five years to an employee with vesting at 25% each anniversary for the next four years.
On December 10, 2013, the Company granted an aggregate of 2,126,000 options to purchase the Company’s Common Stock at an exercise price of $0.1360 per share for five years to employees, with immediate vesting.
On February 6, 2014, the Company granted 2,500,000 options to purchase the Company’s Common Stock at an exercise price of $0.1600 per share for five years to a consultant, with immediate vesting.
The fair value of options granted during the three months ended March 31, 2014 was determined using the Black Scholes Option Pricing Model with the following assumptions: stock price $0.1600, exercise price $0.1600, dividend yield $-0-, volatility of 124.88% and risk free rate of 0.51%.
The Company recorded $547,784 and $455,157 as stock compensation expense for the three month periods ended March 31, 2014  and 2013, respectively, and $1,313,331 and $873,023 for the six month periods ended March 31, 2014 and 2013, respectively, for the vesting portion of all employee options outstanding.   As of March 31, 2014, unrecorded compensation cost related to non-vested awards was $3,808,288, which is expected to be recognized through 2017.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE G - COMMITMENTS AND CONTINGENCIES
	Operating Leases
	The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters.  The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 and expires on May 31, 2016, with the option to extend the lease for two additional three-year periods. The base rent during the initial lease term is $449,142 per annum. The Company also has operating leases for a laboratory in Huddersfield, England, which is currently inactive and Calverton, New York. The Huddersfield lease is currently on month to month.  The Calverton lease is from February 1, 2014 through October 31, 2014, with the option to renew for additional one year periods.  The base rent during the initial lease term is $2,850 per year.  Total rent expense for the three and six month periods ended March 31, 2014 were $126,300 and $254,983, respectively.  Total rent expense for the three and six month periods ended March 31, 2013 were $72,963 and $144,548, respectively.
	Employment Agreement
	The Company has an employment agreement with the Chief Executive Officer as disclosed in the notes to consolidated financial statements included in its Annual Report on Form 10-K and Form 10-K/A for the fiscal year ended September 30, 2013.
	Litigation
	From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business.
	Demodulation, Inc. v. Applied DNA Sciences, Inc., et al. (Civil Action No. 2:11-00296-WJM-MF, District of New Jersey):
	On May 18, 2011, the Company was served with a complaint in a lawsuit brought by Demodulation, Inc. against the Company, Corning Incorporated, Alfred University, and Alfred Technology Resources, Inc.  On July 8, 2011, the Company filed a motion to dismiss the complaint.  In response, on August 3, 2011, Demodulation filed an amended complaint.  Demodulation alleged that it was unable to bring its microwire technology to market due to the wrongful acts of defendants, who allegedly conspired to steal Demodulation’s trade secrets and other intellectual property and to interfere in its business opportunities.  Of the seventeen claims alleged in the amended complaint, five were asserted against the Company, including alleged misappropriation of trade secrets, antitrust violations, civil RICO, and patent infringement.  The Company believes these claims are without merit.
	On January 27, 2012, the Company filed a motion to dismiss the amended complaint for failure to state a claim and on other grounds.  On December 12, 2012, the Court entered an order on the Company’s motion to dismiss.  The Court granted in part and denied in part the Company’s motion, dismissing four out of the five claims asserted against the Company, without prejudice, leaving only the patent infringement claim.  Subsequently, the parties stipulated to sever the patent infringement claim against the Company from the claims against the other defendants.  The Court entered an order severing the patent claim on February 20, 2013, and terminated the main lawsuit against the Company.  Demodulation may seek to re-file its patent claim as a separate action, but to date has not done so.  If Demodulation re-files its action, the Company intends to vigorously defend the action.  The Company is unable to express an opinion with respect to the likelihood of an unfavorable outcome or to estimate the amount or range of potential loss if the outcome should be unfavorable, should Demodulation re-file its action, or whether it will re-file it.
	SmartWater, Ltd. v. Applied DNA Sciences, Inc. (Civil Action No. 12-05731-JS-AKT, Eastern District of New York)
	On June 6, 2012, a complaint for patent infringement was filed against the Company by SmartWater, Ltd. in the United States District Court for the District of Massachusetts. It alleged that the Company infringed one or more claims under two of SmartWater’s patents by selling or offering for sale, manufacturing and using certain of the Company’s products, by inducing others to infringe and by contributing to infringement by others. Prior to serving the complaint, on August 24, 2012, SmartWater voluntarily dismissed the complaint and refiled a similar complaint in the United States District Court for the Southern District of Florida, No. 12-611660-DMM. On August 30, 2012, SmartWater served the Company with the complaint. The refiled complaint seeks injunctive relief with respect to one of the patents as well as awards of damages and attorneys’ fees with respect to the alleged infringement of both patents.
	The Company filed a motion to dismiss and a motion to transfer the action to the United States District Court for the Eastern District of New York. On November 19, 2012, the Court granted the Company’s motion to transfer. Following the transfer, but prior to a decision on the Company’s motion to dismiss, on June 26, 2013, SmartWater moved for leave to file an amended complaint asserting additional allegations in support of its claims. By memorandum and order dated September 27, 2013, the Court granted in part, and denied in part, SmartWater’s motion. The Court held that SmartWater had adequately stated claims for direct infringement of both patents at issue, but had not adequately stated claims for contributory infringement of the patents, or induced infringement with respect to one of the patents, and therefore dismissed them. On October 10, 2013, the Company filed its (i) answer to the amended complaint, as modified by the Court’s September 27, 2013 order, and (ii) counterclaims. On October 31, 2013, the Company filed an amended answer and counterclaims. The Company and SmartWater have filed motions for reconsideration of a portion of the Court’s order. These motions seek a determination of whether SmartWater’s remaining claim for induced infringement of one of the patents should survive, or be dismissed because the patent expired before the Company had notice of it. In addition, the parties are now engaged in discovery.  On January 10, 2014, the Company filed a second amended answer and counterclaims to which SmartWater replied on January 24, 2014.
	The Company believes the claims are without merit and intends to defend the action vigorously. We are unable to express our opinion with respect to the likelihood of an unfavorable outcome or to estimate the amount or range of potential loss if the outcome should be unfavorable.

FAIR_VALUE

FAIR VALUE	6 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
FAIR VALUE	'
	NOTE H - FAIR VALUE
	The carrying value of cash, accounts receivable, accounts payable and accrued expenses approximate estimated fair values because of their short maturities.
	The carrying value of the warrant liability is determined using the Binomial Lattice option pricing model as described in Note A. Certain assumptions used in the calculation of the warrant liability represent level-3 unobservable inputs. The Company did not have any assets or liabilities categorized as Level 1 or 2 as of March 31, 2014.
	The following table summarizes the activity of Level 3 inputs measured on a recurring basis:
	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)	Six Months Ended March 31,
		2014				2013
	Balance at October 1, 2012 and 2013	$	2,643,449		$	—
	Issuance of Series A and B Warrants		—			1,181,324
	Adjustment resulting from change in value recognized in earnings (a)		2,178,859			6,852,518
	Reclassification to equity upon exercise		(2,455,042	)		—
	Balance at March 31,	$	2,367,266		$	8,033,842
	(a)  Adjustment resulting from change in fair value  is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to liabilities held at the reporting date. The unrealized gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

SUMMARY_OF_ACCOUNTING_POLICIES1

SUMMARY OF ACCOUNTING POLICIES (Policies)	6 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Business and Basis of Presentation	'
	Business and Basis of Presentation
	On September 16, 2002, Applied DNA Sciences, Inc. (the “Company”) was incorporated under the laws of the State of Nevada. Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware.  The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe.  To date, the Company has had a limited operating history, and as a result, its operations have produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses.  Consequently, its operations are subject to all the risks inherent in the establishment of a biotechnology company. For the period from inception through March 31, 2014, the Company has accumulated losses of $195,735,697.
	The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Applied DNA Operations Management, Inc., APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations.
Use of Estimates	'
	Use of Estimates
	The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures.  Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  The most complex and subjective estimates include; recoverability of long-lived assets, including the value assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies and allowance for doubtful accounts.  Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the condensed consolidated interim financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”).  ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured.  Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts.  Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded.  The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required.  At March 31, 2014 and September 30, 2013, the Company recorded deferred revenue of $415,989 and $148,503, respectively.
	Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer.  Consideration received is allocated among the separate units of accounting based on their respective selling prices.  The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available.  The applicable revenue recognition criteria are then applied to each of the units.
	Revenue for a government contract award, which supports our development efforts on specific projects, is recognized as milestones are achieved as per the contract.  The Company recognized revenue of approximately $25,000 and $50,000 from this contract award during the three and six month periods ended March 31, 2014, respectively.
Cash Equivalents	'
	Cash Equivalents
	For the purpose of the accompanying unaudited condensed consolidated financial statements, all highly liquid investments with a maturity of three months or less are considered to be cash equivalents.
Accounts Receivable	'
	Accounts Receivable
	The Company provides an allowance for doubtful accounts equal to the estimated uncollectible amounts.  The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable.  It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change.  At March 31, 2014 and September 30, 2013, the Company has an allowance for doubtful accounts of $36,757 and $62,415, respectively.  The Company writes off receivables that are deemed uncollectible.  The Company wrote-off $16,801 and $41,801, respectively, of accounts receivable that was previously reserved for during the three and six month periods ended March 31, 2014.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns.  Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes include, but not limited to, accounting for intangibles, warrants, equity based compensation and depreciation and amortization.
	The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all of the deferred tax asset will not be realized.  During the year ended September 30, 2013 and the three and six months ended March 31, 2014, the Company incurred losses from operations. Based upon these results and the trends in the Company’s performance projected for the remainder of fiscal year 2014, it is more likely than not that the Company will not realize any benefit from the deferred tax assets recorded by the Company in previous periods.  Management makes judgments as to the interpretation of tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability.  In management’s opinion, adequate provisions for income taxes have been made for all years.  If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.  The Company has identified its federal tax return and its state tax return in New York as “major” tax jurisdictions.  Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company condensed consolidated financial statements.
	The Company’s evaluation was performed for tax years 2009 through 2012.  The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position.  It is the Company’s policy to accrue interest and penalties on unrecognized tax benefits as components of income tax provision.  The Company did not have any accrued interest or penalties as of March 31, 2014 and September 30, 2013.
Property Plant and Equipment	'
	Property Plant and Equipment
	Property plant and equipment are stated at cost and depreciated using the straight line method over their estimated useful lives.  The estimated useful lives for computer equipment, lab equipment and furniture is 3 to 5 years and leasehold improvements are amortized over the shorter of their useful life or the lease term. Property plant and equipment consist of:
		March 31,		September 30,
		2014		2013
		(unaudited)
	Computer equipment	$	69,182	$	43,555
	Lab equipment		739,889		657,735
	Furniture		164,997		164,997
	Leasehold improvements		248,931		239,337
	Total		1,222,999		1,105,624
	Accumulated depreciation		575,507		409,629
	Property and equipment, net	$	647,492	$	695,995
	Depreciation expense for the three and six month periods ended March 31, 2014 was $83,864 and $165,878, respectively.  Depreciation expense for the three and six month periods ended March 31, 2013 was $21,830 and $42,825, respectively.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company accounts for its long-lived assets in accordance with ASC 360, Property, Plant and Equipment (“ASC 360”).  ASC 360 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The Company evaluates its long lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period.  The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows.  Should impairment in value be indicated, the carrying value of long-lived assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset.  ASC 360 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.
Segment Information	'
	Segment Information
	The Company follows the provisions of ASC 280, Segment Reporting (“ASC 280”).  ASC 280 establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders.  ASC 280 also establishes standards for related disclosures about products and services and geographic areas.  Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance.  The information disclosed herein, materially represents all of the financial information related to the Company’s single principal operating segment.
Net Loss Per Share	'
	Net Loss Per Share
	The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share.  Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period.  Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.
	For the three and six months ended March 31, 2014 and 2013, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.
	Fully diluted shares outstanding were 951,183,299 and 939,779,709 for the three and six month periods ended March 31, 2014, respectively.
	Fully diluted shares outstanding were 813,157,960 and 797,751,816 for the three and six month periods ended March 31, 2013, respectively.
Stock Based Compensation	'
	Stock Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation (“ASC 718”).  ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values.  Under the provisions of ASC 718, stock-based compensation costs is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant).  The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions:  expected volatility, dividend rate, risk free interest rate and the expected life.  The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.  Stock-based compensation expense recognized under ASC 718 for the three and six month periods ended March 31, 2014 were $547,784 and $1,313,331, respectively, and for the three and six month periods ended March 31, 2013 were $455,157 and $873,023, respectively.
	As of March 31, 2014, 192,484,972 employee stock options were outstanding with options to purchase 131,107,972 shares vested and exercisable.
Concentrations	'
	Concentrations
	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables.  The Company places its cash and temporary cash investments with high credit quality institutions.  At times, such investments may be in excess of the FDIC insurance limit.
	The Company’s revenues earned from sale of products and services for the three month period ended March 31, 2014 included an aggregate of 16% from one customer of the Company’s total revenues. During the six month period ended March 31, 2014 no customers represented 10% or greater of the Company’s total revenues.
	The Company’s revenues earned from the sale of products and services for the three and six month periods ended March 31, 2013 included an aggregate of 66% and 59% from one and four customers of the Company’s total revenues, respectively.
	Three customers accounted for 61% and 43% of the Company’s total accounts receivable at March 31, 2014 and September 30, 2013, respectively.
Research and Development	'
	Research and Development
	The Company accounts for research and development costs in accordance with the ASC 730, Research and Development (“ASC 730”).  Under ASC 730, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.  The Company incurred research and development expenses of $359,782 and $176,485 for the three month periods ended March 31, 2014 and 2013, respectively, and $819,086 and $324,151 for the six month periods ended March 31, 2014 and 2013, respectively.
Advertising	'
	Advertising
	The Company follows the policy of charging the costs of advertising to expense as incurred.  The Company charged to operations $22,477 and $99,352 as advertising costs for the three month periods ended March 31, 2014 and 2013, respectively, and $74,918 and $136,811 for the six month periods ended March 31, 2014 and 2013, respectively.
Intangible Assets	'
	Intangible Assets
	The Company amortizes its intangible assets using the straight-line method over their estimated period of benefit.  The estimated useful life for patents is five years while other intellectual property uses a seven year useful life. The Company periodically evaluates the recoverability of intangible assets and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists.  All of the Company’s intangible assets are subject to amortization.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company’s financial instruments are primarily composed of cash, accounts receivable, accounts payable and accrued liabilities, and warrants. The fair value of cash, accounts receivable, accounts payable and accrued liabilities, as reflected in the condensed consolidated balance sheet, approximate its fair value due to the short-term maturity of these instruments.
	The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.
	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.
	The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.
	For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.
	As of March 31, 2014, there were no transfers in or out of Level 3 from other levels.
	The fair value of each warrant is estimated using the Binomial Lattice option pricing model. Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility, in isolation, can significantly increase or decrease the fair value of the warrant. See Note H.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.
Subsequent Events	'
	Subsequent Events
	The Company has evaluated events that occurred subsequent to the balance sheet date and through the date the financial statements were available to be issued. Management concluded that no subsequent events required disclosure in the condensed consolidated financial statements.

SUMMARY_OF_ACCOUNTING_POLICIES2

SUMMARY OF ACCOUNTING POLICIES (Tables)	6 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of property plant and equipment	'
		March 31,		September 30,
		2014		2013
		(unaudited)
	Computer equipment	$	69,182	$	43,555
	Lab equipment		739,889		657,735
	Furniture		164,997		164,997
	Leasehold improvements		248,931		239,337
	Total		1,222,999		1,105,624
	Accumulated depreciation		575,507		409,629
	Property and equipment, net	$	647,492	$	695,995

ACCOUNTS_PAYABLE_AND_ACCRUED_L1

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	6 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Schedule of accounts payable and accrued liabilities	'
		March 31,
		2014		September 30,
		(unaudited)		2013
	Accounts payable	$	986,281	$	641,302
	Accrued consulting fees		102,500		102,500
	Accrued salaries payable		152,413		220,175
	Other accrued expenses		78,149		3,000
	Total	$	1,319,343	$	966,977

STOCK_OPTIONS_AND_WARRANTS_Tab

STOCK OPTIONS AND WARRANTS (Tables)	6 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of summary of the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the company	'
							Warrants
							Outstanding			Weighted				Exercisable
							Remaining			Average		Weighted		Weighted
		Exercise		Number			Contractual			Exercise		Average		Average
		Prices		Outstanding			Life (Years)			Price		Exercisable		Exercise Price
	$	0.04			2,000,000			1. 42		$	0.04		2,000,000	$	0.04
	$	0.0441			510,784			3.29		$	0.0441		510,784	$	0.0441
	$	0.0475			3,789,489			4.29		$	0.0475		3,789,489	$	0.0475
	$	0.0553			226,081			3.78		$	0.0553		226,081	$	0.0553
	$	0.071			1,000,000			0.82		$	0.071		1,000,000	$	0.071
	$	0.09			6,900,000			2.42		$	0.09		6,900,000	$	0.09
	$	0.179			100,000			1.6		$	0.179		100,000	$	0.179
	$	0.214			100,000			2.1		$	0.214		100,000	$	0.214
	$	0.2431			22,411,764			4.3		$	0.2431		22,411,764	$	0.2431
					37,038,118			3.67		$	0.1748		37,038,118	$	0.1748
Schedule of transactions involving warrants	'
			Number of			Weighted Average
			Shares			Price Per Share
	Balance at October 1, 2013			59,033,305		$	0.0196
	Granted			—			—
	Exercised			(18,695,187	)		(0.2320	)
	Cancelled or expired			(3,300,000	)		(0.2330	)
	Balance,  March 31, 2014			37,038,118		$	0.1748
Schedule of summary of changes in options outstanding and the related prices for the shares of common stock issued to employees of company	'
		Options Outstanding								Options Exercisable
		Exercise		Number			Weighted Average			Weighted Average		Number		Weighted
		Prices		Outstanding			Remaining			Exercise Price		Exercisable		Average
							Contractual							Exercise Price
							Life (Years)
	$	0.05			24,000,000			1.1		$	0.05		24,000,000	$	0.05
	$	0.0585			50,000,000			4.29		$	0.0585		50,000,000	$	0.0585
	$	0.06			30,000,000			1.26		$	0.06		30,000,000	$	0.06
	$	0.065			634,825			2.68		$	0.065		634,825	$	0.065
	$	0.068			4,770,000			2.67		$	0.068		4,770,000	$	0.068
	$	0.07			2,850,000			1.17		$	0.07		2,300,000	$	0.07
	$	0.0866			7,377,000			4.71		$	0.0866		2,000,000	$	0.0866
	$	0.09			1,500,000			1.42		$	0.09		1,500,000	$	0.09
	$	0.097			56,777,780			4.71		$	0.097		3,777,780	$	0.097
	$	0.11			5,400,000			4.21		$	0.11		5,400,000	$	0.11
	$	0.116			250,000			4.73		$	0.116		—	$	—
	$	0.117			2,000,000			4.73		$	0.117		—	$	—
	$	0.136			2,126,000			4.74		$	0.136		2,126,000	$	0.136
	$	0.16			2,500,000			4.83		$	0.16		2,500,000	$	0.16
	$	0.1799			2,099,367			3.67		$	0.1799		2,099,367	$	0.1799
	$	0.193			100,000			4.25		$	0.193		—	$	—
	$	0.2			100,000			4.13		$	0.2		—	$	—
					192,484,972			3. 45		$	0.0765		131,107,972	$	0.067
Schedule of summary of transactions involving stock options issued to employees	'
			Number of			Weighted Average			Aggregate
			Shares			Exercise			Intrinsic
						Price Per			Value
						Share
	Outstanding at October 1, 2013			121,454,192		$	0.063
	Granted			71,030,780			0.0999
	Exercised			—			—
	Expired			—			—
	Outstanding at March 31, 2014			192,484,972		$	0.0765
	Vested at March 31, 2014			131,107,972					$	0.067
	Non-vested at March 31, 2014			61,377,000					$	0.036

FAIR_VALUE_Tables

FAIR VALUE (Tables)	6 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of fair value measurements of common stock warrants using significant unobservable inputs (Level 3)	'
	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)	Six Months Ended March 31,
		2014				2013
	Balance at October 1, 2012 and 2013	$	2,643,449		$	—
	Issuance of Series A and B Warrants		—			1,181,324
	Adjustment resulting from change in value recognized in earnings (a)		2,178,859			6,852,518
	Reclassification to equity upon exercise		(2,455,042	)		—
	Balance at March 31,	$	2,367,266		$	8,033,842
	(a)  Adjustment resulting from change in fair value  is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to liabilities held at the reporting date. The unrealized gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

SUMMARY_OF_ACCOUNTING_POLICIES3

SUMMARY OF ACCOUNTING POLICIES - Summary of property and equipment (Details) (USD $)	Mar. 31, 2014	Sep. 30, 2013
Property, Plant and Equipment [Line Items]	'	'
Total	$1,222,999	$1,105,624
Accumulated depreciation	575,507	409,629
Property and equipment, net	647,492	695,995
Computer equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	69,182	43,555
Lab equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	739,889	657,735
Furniture	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	164,997	164,997
Leasehold improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Total	$248,931	$239,337

SUMMARY_OF_ACCOUNTING_POLICIES4

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Sep. 30, 2013
Accounting Policies [Line Items]	'	'	'	'	'
Accumulated losses	($195,735,697)	'	($195,735,697)	'	($186,693,611)
Deferred revenue	415,989	'	415,989	'	148,503
Revenue for a government contract award	25,000	'	50,000	'	'
Allowance on accounts receivable (in dollars)	36,757	'	36,757	'	62,415
Previously reserved accounts receivable , write-off	16,801	'	41,801	'	'
Depreciation method	'	'	'Straight line method	'	'
Estimated useful lives	'	'	'3 to 5 years	'	'
Depreciation expense	83,864	21,830	165,878	42,825	'
Amortization method	'	'	'Straight-line method	'	'
Fully diluted shares outstanding (in shares)	951,183,299	813,157,960	939,779,709	797,751,816	'
Stock-based compensation expense	547,784	455,157	1,313,331	873,023	'
Research and development expenses	359,782	176,485	819,086	324,151	'
Advertising costs	$22,477	$99,352	$74,918	$136,811	'
Employee Stock Options | Incentive Stock Plan 2005	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'
Employee stock options outstanding (in shares)	192,484,972	'	192,484,972	'	121,454,192
Number of shares vested and exercisable (in shares)	131,107,972	'	131,107,972	'	'
Patents	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'
Estimated useful life (in years)	'	'	'5 years	'	'
Intellectual property	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'
Estimated useful life (in years)	'	'	'7 years	'	'

SUMMARY_OF_ACCOUNTING_POLICIES5

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1)	6 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2013	Mar. 31, 2014	Sep. 30, 2013
	Total Revenue	Total Revenue	Total Revenue	Total Revenue	Accounts Receivable	Accounts Receivable
		Customer One	Customer One	Customer Four	Customer Three	Customer Three
Concentration Risk [Line Items]	'	'	'	'	'	'
Percentage of total revenue and accounts receivable from various customers	'	16.00%	66.00%	59.00%	61.00%	43.00%
Total revenue, benchmark description	'No customers represented 10% or greater of the Company's total revenues.	'	'	'	'	'

LIQUIDITY_AND_MANAGEMENTS_PLAN1

LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Sep. 30, 2013	Sep. 30, 2012
Liquidity And Management Plan [Abstract]	'	'	'	'	'	'
Accumulated deficit	($195,735,697)	'	($195,735,697)	'	($186,693,611)	'
Net loss	-2,750,436	-3,127,631	-9,042,086	-11,832,388	'	'
Operating cash flow	'	'	-4,262,536	-3,889,111	'	'
Working capital	967,081	'	967,081	'	'	'
Cash and cash equivalents	$1,988,184	$4,405,610	$1,988,184	$4,405,610	$6,360,301	$724,782

ACCOUNTS_PAYABLE_AND_ACCRUED_L2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) (USD $)	Mar. 31, 2014	Sep. 30, 2013
Payables and Accruals [Abstract]	'	'
Accounts payable	$986,281	$641,302
Accrued consulting fees	102,500	102,500
Accrued salaries payable	152,413	220,175
Other accrued expenses	78,149	3,000
Total	$1,319,343	$966,977

WARRANT_LIABILITY_Detail_Textu

WARRANT LIABILITY (Detail Textuals) (USD $)	3 Months Ended		6 Months Ended		0 Months Ended		6 Months Ended		0 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Feb. 11, 2014	Dec. 16, 2013	Mar. 31, 2014	Mar. 31, 2014	Dec. 16, 2013	Dec. 16, 2013
					Common Stock	Warrants	Warrants	Series B Warrants	Crede CG III, Ltd	Crede CG III, Ltd
									Series A Warrants	Series B Warrants
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'	'
Cashless exercise of warrants	'	'	18,695,187	'	1,000,000	'	'	22,411,764	10,695,187	7,000,000
Fair value of warrants	'	'	'	'	'	$2,455,042	'	$2,367,266	'	'
Method used for determining fair value of warrants	'	'	'	'	'	'Binomial Lattice model	'Binomial Lattice model	'	'	'
Fair value of common stock (in dollars per share)	'	'	'	'	'	$0.18	$0.13	'	'	'
Dividend yield (in percent)	'	'	'	'	'	0.00%	0.00%	'	'	'
Number of expected term (in years)	'	'	'	'	'	'4 years 6 months 18 days	'4 years 3 months 18 days	'	'	'
Risk free interest rate (in percent)	'	'	'	'	'	1.55%	1.32%	'	'	'
Expected volatility (in percent)	'	'	'	'	'	118.89%	138.87%	'	'	'
Exercise price of warrants (in dollars per warrant)	'	'	'	'	'	$0.24	$0.24	'	'	'
Change in fair value of warrant liability	($455,899)	$519,919	$2,178,859	$6,852,518	'	$1,288,752	'	'	'	'

CAPITAL_STOCK_Detail_Textuals

CAPITAL STOCK (Detail Textuals) (USD $)	Mar. 31, 2014	Sep. 30, 2013	Jan. 27, 2012	Jan. 26, 2012
Stockholders' Equity Note [Abstract]	'	'	'	'
Common stock, shares authorized	1,350,000,000	1,350,000,000	1,350,000,000	800,000,000
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00	$0.00	'
Common stock, shares issued	808,596,863	786,526,955	'	'
Common stock, shares outstanding	808,596,863	786,526,955	'	'

CAPITAL_STOCK_Detail_Textuals_

CAPITAL STOCK (Detail Textuals 1) (USD $)	6 Months Ended		0 Months Ended	1 Months Ended		0 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Feb. 11, 2014	Dec. 20, 2013	Dec. 16, 2013	Dec. 16, 2013	Dec. 16, 2013
		Series B Warrants	Common Stock	Consulting agreement	Crede CG III, Ltd	Crede CG III, Ltd	Crede CG III, Ltd
				Common Stock		Series A Warrants	Series B Warrants
Stockholders' Equity Note [Line Items]	'	'	'	'	'	'	'
Cashless exercise of warrants	18,695,187	22,411,764	1,000,000	'	'	10,695,187	7,000,000
Number of common stock called by warrants	'	'	746,835	'	18,823,073	'	'
Number of shares issued for services	'	'	'	2,500,000	'	'	'
Fair value of shares issued	'	'	'	$337,500	'	'	'

STOCK_OPTIONS_AND_WARRANTS_Cha

STOCK OPTIONS AND WARRANTS - Changes in warrants outstanding and related prices (Details)	6 Months Ended
	Mar. 31, 2014	Sep. 30, 2013
Class of Warrant or Right [Line Items]	'	'
Number Outstanding	37,038,118	59,033,305
Warrants Outstanding Remaining Contractual Life (Years)	'3 years 8 months 1 day	'
Weighted Average Exercise Price	0.1748	'
Weighted Average Exercisable	37,038,118	'
Exercisable Weighted Average Exercise Price	0.1748	'
Exercise price $0.0400	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Prices	0.04	'
Number Outstanding	2,000,000	'
Warrants Outstanding Remaining Contractual Life (Years)	'1 year 5 months 1 day	'
Weighted Average Exercise Price	0.04	'
Weighted Average Exercisable	2,000,000	'
Exercisable Weighted Average Exercise Price	0.04	'
Exercise price $0.0441	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Prices	0.0441	'
Number Outstanding	510,784	'
Warrants Outstanding Remaining Contractual Life (Years)	'3 years 3 months 14 days	'
Weighted Average Exercise Price	0.0441	'
Weighted Average Exercisable	510,784	'
Exercisable Weighted Average Exercise Price	0.0441	'
Exercise price $0.0475	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Prices	0.0475	'
Number Outstanding	3,789,489	'
Warrants Outstanding Remaining Contractual Life (Years)	'4 years 3 months 15 days	'
Weighted Average Exercise Price	0.0475	'
Weighted Average Exercisable	3,789,489	'
Exercisable Weighted Average Exercise Price	0.0475	'
Exercise price $0.0553	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Prices	0.0553	'
Number Outstanding	226,081	'
Warrants Outstanding Remaining Contractual Life (Years)	'3 years 9 months 11 days	'
Weighted Average Exercise Price	0.0553	'
Weighted Average Exercisable	226,081	'
Exercisable Weighted Average Exercise Price	0.0553	'
Exercise price $0.0710	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Prices	0.071	'
Number Outstanding	1,000,000	'
Warrants Outstanding Remaining Contractual Life (Years)	'9 months 26 days	'
Weighted Average Exercise Price	0.071	'
Weighted Average Exercisable	1,000,000	'
Exercisable Weighted Average Exercise Price	0.071	'
Exercise price $0.0900	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Prices	0.09	'
Number Outstanding	6,900,000	'
Warrants Outstanding Remaining Contractual Life (Years)	'2 years 5 months 1 day	'
Weighted Average Exercise Price	0.09	'
Weighted Average Exercisable	6,900,000	'
Exercisable Weighted Average Exercise Price	0.09	'
Exercise price $0.1790	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Prices	0.179	'
Number Outstanding	100,000	'
Warrants Outstanding Remaining Contractual Life (Years)	'1 year 7 months 6 days	'
Weighted Average Exercise Price	0.179	'
Weighted Average Exercisable	100,000	'
Exercisable Weighted Average Exercise Price	0.179	'
Exercise price $0.2140	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Prices	0.214	'
Number Outstanding	100,000	'
Warrants Outstanding Remaining Contractual Life (Years)	'2 years 1 month 6 days	'
Weighted Average Exercise Price	0.214	'
Weighted Average Exercisable	100,000	'
Exercisable Weighted Average Exercise Price	0.214	'
Exercise price $0.2431	'	'
Class of Warrant or Right [Line Items]	'	'
Exercise Prices	0.2431	'
Number Outstanding	22,411,764	'
Warrants Outstanding Remaining Contractual Life (Years)	'4 years 3 months 18 days	'
Weighted Average Exercise Price	0.2431	'
Weighted Average Exercisable	22,411,764	'
Exercisable Weighted Average Exercise Price	0.2431	'

STOCK_OPTIONS_AND_WARRANTS_Tra

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details 1) (USD $)	6 Months Ended
	Mar. 31, 2014
Class Of Warrant Or Right, Number Of Shares [Roll Forward]	'
Beginning Balance, Number of Shares	59,033,305
Granted	'
Exercised	-18,695,187
Cancelled or expired	-3,300,000
Ending Balance, Number of Shares	37,038,118
Class Of Warrant Or Right, Weighted Average Price Per Share [Roll Forward]	'
Beginning Balance, Weighted Average Price Per Share	$0.02
Granted	'
Exercised	($0.23)
Cancelled or expired	($0.23)
Ending Balance, Weighted Average Price Per Share	$0.17

STOCK_OPTIONS_AND_WARRANTS_Cha1

STOCK OPTIONS AND WARRANTS - Changes in options outstanding and related prices (Details 2) (Employee Stock Options, Incentive Stock Plan 2005, USD $)	6 Months Ended
	Mar. 31, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	192,484,972	121,454,192
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'3 years 5 months 12 days	'
Options Outstanding, Weighted Average Exercise Price	$0.08	$0.06
Options Exercisable, Number Exercisable	131,107,972	'
Options Exercisable, Weighted Average Exercise Price	$0.07	'
Exercise price $0.0500	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.05	'
Options Outstanding, Number Outstanding	24,000,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'1 year 1 month 6 days	'
Options Outstanding, Weighted Average Exercise Price	$0.05	'
Options Exercisable, Number Exercisable	24,000,000	'
Options Exercisable, Weighted Average Exercise Price	$0.05	'
Exercise price $0.0585	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.06	'
Options Outstanding, Number Outstanding	50,000,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 3 months 14 days	'
Options Outstanding, Weighted Average Exercise Price	$0.06	'
Options Exercisable, Number Exercisable	50,000,000	'
Options Exercisable, Weighted Average Exercise Price	$0.06	'
Exercise price $0.0600	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.06	'
Options Outstanding, Number Outstanding	30,000,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'1 year 3 months 4 days	'
Options Outstanding, Weighted Average Exercise Price	$0.06	'
Options Exercisable, Number Exercisable	30,000,000	'
Options Exercisable, Weighted Average Exercise Price	$0.06	'
Exercise price $0.0650	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.07	'
Options Outstanding, Number Outstanding	634,825	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'2 years 8 months 5 days	'
Options Outstanding, Weighted Average Exercise Price	$0.07	'
Options Exercisable, Number Exercisable	634,825	'
Options Exercisable, Weighted Average Exercise Price	$0.07	'
Exercise price $0.0680	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.07	'
Options Outstanding, Number Outstanding	4,770,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'2 years 8 months 1 day	'
Options Outstanding, Weighted Average Exercise Price	$0.07	'
Options Exercisable, Number Exercisable	4,770,000	'
Options Exercisable, Weighted Average Exercise Price	$0.07	'
Exercise price $0.0700	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.07	'
Options Outstanding, Number Outstanding	2,850,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'1 year 2 months 1 day	'
Options Outstanding, Weighted Average Exercise Price	$0.07	'
Options Exercisable, Number Exercisable	2,300,000	'
Options Exercisable, Weighted Average Exercise Price	$0.07	'
Exercise price $0.0866	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.09	'
Options Outstanding, Number Outstanding	7,377,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 8 months 16 days	'
Options Outstanding, Weighted Average Exercise Price	$0.09	'
Options Exercisable, Number Exercisable	2,000,000	'
Options Exercisable, Weighted Average Exercise Price	$0.09	'
Exercise price $0.0900	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.09	'
Options Outstanding, Number Outstanding	1,500,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'1 year 5 months 1 day	'
Options Outstanding, Weighted Average Exercise Price	$0.09	'
Options Exercisable, Number Exercisable	1,500,000	'
Options Exercisable, Weighted Average Exercise Price	$0.09	'
Exercise price $0.0970	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.10	'
Options Outstanding, Number Outstanding	56,777,780	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 8 months 16 days	'
Options Outstanding, Weighted Average Exercise Price	$0.10	'
Options Exercisable, Number Exercisable	3,777,780	'
Options Exercisable, Weighted Average Exercise Price	$0.10	'
Exercise price $0.1100	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.11	'
Options Outstanding, Number Outstanding	5,400,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 32 months 16 days	'
Options Outstanding, Weighted Average Exercise Price	$0.11	'
Options Exercisable, Number Exercisable	5,400,000	'
Options Exercisable, Weighted Average Exercise Price	$0.11	'
Exercise price $0.1160	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.12	'
Options Outstanding, Number Outstanding	250,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 8 months 23 days	'
Options Outstanding, Weighted Average Exercise Price	$0.12	'
Options Exercisable, Number Exercisable	'	'
Options Exercisable, Weighted Average Exercise Price	'	'
Exercise price $0.1170	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.12	'
Options Outstanding, Number Outstanding	2,000,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 8 months 23 days	'
Options Outstanding, Weighted Average Exercise Price	$0.12	'
Options Exercisable, Number Exercisable	'	'
Options Exercisable, Weighted Average Exercise Price	'	'
Exercise price $0.1360	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.14	'
Options Outstanding, Number Outstanding	2,126,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 8 months 26 days	'
Options Outstanding, Weighted Average Exercise Price	$0.14	'
Options Exercisable, Number Exercisable	2,126,000	'
Options Exercisable, Weighted Average Exercise Price	$0.14	'
Exercise price $ 0.1600	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.16	'
Options Outstanding, Number Outstanding	2,500,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 9 months 29 days	'
Options Outstanding, Weighted Average Exercise Price	$0.16	'
Options Exercisable, Number Exercisable	2,500,000	'
Options Exercisable, Weighted Average Exercise Price	$0.16	'
Exercise price $0.1799	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.18	'
Options Outstanding, Number Outstanding	2,099,367	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'3 years 8 months 1 day	'
Options Outstanding, Weighted Average Exercise Price	$0.18	'
Options Exercisable, Number Exercisable	2,099,367	'
Options Exercisable, Weighted Average Exercise Price	$0.18	'
Exercise price $0.1930	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.19	'
Options Outstanding, Number Outstanding	100,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 3 months	'
Options Outstanding, Weighted Average Exercise Price	$0.19	'
Options Exercisable, Number Exercisable	'	'
Options Exercisable, Weighted Average Exercise Price	'	'
Exercise price $0.2000	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Exercise Prices	$0.20	'
Options Outstanding, Number Outstanding	100,000	'
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'4 years 1 month 17 days	'
Options Outstanding, Weighted Average Exercise Price	$0.20	'
Options Exercisable, Number Exercisable	'	'
Options Exercisable, Weighted Average Exercise Price	'	'

STOCK_OPTIONS_AND_WARRANTS_Tra1

STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 3) (Employee Stock Options, USD $)	0 Months Ended	6 Months Ended
	Oct. 14, 2013	Mar. 31, 2014
		Incentive Stock Plan 2005
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Outstanding at October 1, 2013	'	121,454,192
Granted	7,377,000	71,030,780
Exercised	'	'
Expired	'	'
Outstanding at March 31, 2014	'	192,484,972
Vested at March 31, 2014	'	131,107,972
Non-vested at March 31, 2014	'	61,377,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'
Outstanding at October 1, 2013	'	$0.06
Granted	$0.09	$0.10
Exercised	'	'
Expired	'	'
Outstanding at March 31, 2014	'	$0.08
Aggregate Intrinsic Value, Vested at March 31, 2014	'	$0.07
Aggregate Intrinsic Value, Non-vested at March 31, 2014	'	$0.04

STOCK_OPTIONS_AND_WARRANTS_Tra2

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Detail Textuals)	6 Months Ended	0 Months Ended	6 Months Ended		0 Months Ended
	Mar. 31, 2014	Feb. 11, 2014	Mar. 31, 2014	Dec. 16, 2013	Dec. 16, 2013	Dec. 16, 2013
		Common Stock	Series B Warrants	Crede CG III, Ltd	Crede CG III, Ltd	Crede CG III, Ltd
					Series A Warrants	Series B Warrants
Class of Warrant or Right [Line Items]	'	'	'	'	'	'
Cashless exercise of warrants	18,695,187	1,000,000	22,411,764	'	10,695,187	7,000,000
Number of common stock called by warrants	'	746,835	'	18,823,073	'	'

STOCK_OPTIONS_AND_WARRANTS_Emp

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) (Employee Stock Options, Incentive Stock Plan 2005)	6 Months Ended
	Mar. 31, 2014
Employee Stock Options | Incentive Stock Plan 2005	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Aggregate number of shares of common stock that can be issued as stock awards and stock option	350,000,000
Number of common stock shares that can be covered by awards made to any participant per period	50,000,000
Number of shares issued	12,675,000
Options to purchase Shares under the 2005 Incentive Stock Plan	198,488,972

STOCK_OPTIONS_AND_WARRANTS_Emp1

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 2) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Oct. 14, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 02, 2013

Nov. 28, 2013

Oct. 14, 2013

Oct. 17, 2013

Oct. 17, 2013

Dec. 10, 2013

Oct. 14, 2013

Oct. 17, 2013

Feb. 06, 2014

Employee Stock Options

Employee Stock Options

Employee Stock Options

Employee Stock Options

Employee Stock Options

Employee Stock Options

Employee Stock Options

Employee Stock Options

Employee Stock Options

Employee Stock Options

Employee Stock Options

Employee Stock Options

Incentive Stock Plan 2005

Vesting on each anniversary for next four years

Vesting on each anniversary for next four years

Vesting on each anniversary for next four years

Vesting on each anniversary for next four years

Vesting on each anniversary for next four years

Immediate vesting

Immediate vesting

Immediate vesting

Immediate vesting

Dr. James A. Hayward

Dr. Ming-Hwa Liang

Non-employee board of director members

Consultant

Incentive Stock Plan 2005

Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options granted

'

'

'

'

7,377,000

'

71,030,780

2,000,000

250,000

'

50,000,000

3,000,000

2,126,000

'

3,777,780

2,500,000

Exercise price per share of options granted

'

'

'

'

$0.09

'

$0.10

$0.12

$0.12

'

$0.10

$0.10

$0.14

'

$0.10

$0.16

Vesting period of options issued

'

'

'

'

'5 years

'

'

'5 years

'5 years

'

'5 years

'5 years

'5 years

'

'5 years

'5 years

Number of options vested

'

'

'

'

'

'

131,107,972

'

'

5,377,000

'

'

'

2,000,000

'

'

Percentage of vesting in each year

'

'

'

'

'

'

'

25.00%

25.00%

25.00%

25.00%

25.00%

'

'

'

'

Fair value of options, stock price

'

'

'

'

'

$0.16

'

'

'

'

'

'

'

'

'

'

Fair value of options, exercise price

'

'

'

'

'

$0.16

'

'

'

'

'

'

'

'

'

'

Fair value of options, dividend yield

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

Fair value of options, volatility rate

'

'

'

'

'

124.88%

'

'

'

'

'

'

'

'

'

'

Fair value of options, risk free rate

'

'

'

'

'

0.51%

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

$547,784

$455,157

$1,313,331

$873,023

'

'

'

'

'

'

'

'

'

'

'

'

Unrecorded compensation cost related to non-vested awards

$3,808,288

'

$3,808,288

'

'

'

'

'

'

'

'

'

'

'

'

'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Detail Textuals) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended
	Jun. 15, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
	sqft			Claim
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'
Area of property under operating lease	30,000	'	'	'	'
Extended operating lease for two additional period	'3 years	'	'	'	'
Base rent during initial lease term per annum	$449,142	'	'	$2,850	'
Total lease rental expenses	'	$126,300	$72,963	$254,983	$144,548
Number of claims alleged in amended complaint	'	'	'	17	'
Number of claims asserted against company	'	'	'	5	'
Number of claims dismissed against asserted claims	'	'	'	4	'

FAIR_VALUE_Fair_Value_Measurem

FAIR VALUE - Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3) (Details) (Common Stock Warrants, USD $)	6 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Common Stock Warrants	'		'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'		'
Balance at October 1,	$2,643,449		'
Issuance of Series A and B Warrants	'		1,181,324
Adjustment resulting from change in value recognized in earnings	2,178,859	[1]	6,852,518	[1]
Reclassification to equity upon exercise	-2,455,042		'
Balance at March 31,	$2,367,266		$8,033,842
[1]	Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to liabilities held at the reporting date. The unrealized gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.